Munich, Germany: Brainloop has announced that French Nanobiotix S.A., a leader in the development of cancer treatments based on nanotherapeutics, has used Brainloop’s Secure Dataroom to negotiate an exclusive licensing and collaboration agreement with PharmaEngine, Inc. (Taipei, Taiwan). PharmaEngine, Inc., a specialty pharma company focused on the development of in-licensed oncology drugs, received exclusive rights to develop and commercialize Nanobiotix’ lead product NBTXR3 in the Asian-Pacific region, a transaction that was announced in August 2012. The goal of the cooperation is to accelerate NBTXR3 clinical program development and to develop the Asian market.
- ZOE DAVIES, REALWIRE IN PARTNERSHIP WITH VIGILANCE
- InfoSecurity
- Posted On